<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101708</url>
  </required_header>
  <id_info>
    <org_study_id>2019SDU-QILU-G099</org_study_id>
    <nct_id>NCT04101708</nct_id>
  </id_info>
  <brief_title>A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients</brief_title>
  <official_title>A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the effectiveness and safety of high-dose
      dual therapy and half-dose clarithromycin-containing bismuth quadruple therapy in elderly
      patients for eradicating H.pylori.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori plays an important role in many diseases such as peptic ulcer disease and
      MALT lymphomas. And the prevalence of H. pylori remains high in developing
      countries,including China.

      Clarithromycin-containing bismuth quadruple therapy has been recommended as the first-line
      therapy for H pylori infection in China. However, its expensive cost and high
      antibiotic‐related adverse reactions are always haunting us. In 2018,a research from NanFang
      hospital(China）revealed that 250mg clarithromycin is as effective as 500mg clarithromycin，at
      the same time，causes less adverse reactions. On the othe hand,previous studies reported a new
      regimen called large dose dual therapy（generally contains a PPI and amoxicillin),while some
      of them have achieved very good results,especially in Taiwan.

      However, specific data on anti-H.pylori treatments in elderly people are very lacking.So,we
      aim to assess and compare the effectiveness and tolerability of high-dose dual therapy and
      half-dose clarithromycin-containing bismuth quadruple therapy in elderly patients.Considering
      the difference of drug metabolism between eldery and young people，a satisfactory result may
      be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2019</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eradication rate of the two groups</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>high dose dual group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in high dose dual group will receive lansoprazole (Takepron) 30mg po qid, amoxicillin 750mg po qid for 14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>half-dose clarithromycin-containing bismuth quadruple group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in half-dose clarithromycin-containing bismuth quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 250mg po bid for 14d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole, Amoxicillin</intervention_name>
    <description>high dose dual regimen</description>
    <arm_group_label>high dose dual group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate</intervention_name>
    <description>half-dose clarithromycin-containing bismuth quadruple regimen</description>
    <arm_group_label>half-dose clarithromycin-containing bismuth quadruple group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, aged greater than 65 , with positive H. pylori infection that was not
             eradicated by previous therapies are included. The H. pylori infection is confirmed by
             the positive rapid urease test or 13C-breath test.

        Exclusion Criteria:

          -  Patients with significant underlying disease including liver, cardiac, pulmonary, and
             renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric
             surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,
             NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of
             allergic reactions to any of the medications used in this protocol. Patients
             previously treated with H. pylori eradication regimens or those unwilling to
             participate in the study were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <phone_ext>15588818685</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hosipital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <investigator>
      <last_name>Boshen Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yueyue Li, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>elderly,helicobacter pylori eradication,dual therapy,half-dose clarithromycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

